Tango Therapeutics, Inc.
TNGX
$-0.45
Change (1 day)
$13.01
Year High
$2.70
Year Low
Categories
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Tango Therapeutics, Inc. (TNGX) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -27,465,000 | 149.46 M | 402.57 M | 346.54 M | |
| 2022 | 2 M | -18,837,000 | 186.99 M | 436.47 M | 375.27 M |
| 2021 | 2 M | -141,242,000 | 155.41 M | 500.16 M | 492.34 M |
| 2020 | 2 M | -20,497,000 | 168.65 M | 207.25 M | 193.63 M |
| 2019 | -15,005,000 | 47.86 M | 55.76 M | 41.66 M |